Business Wire

CA-GRINDR

Share
Grindr Brings Free At-Home HIV Self-Test Kits to Europe for the First Time With New Programs in Georgia and Ireland

At the outset of European testing week, Grindr Inc. (NYSE: GRND), the world’s largest social network for the LGBTQ+ community, today announced the launch of its new partnerships with Equality Movement and MPOWER to connect Grindr users directly with HIV self-test kits in Georgia and Ireland, respectively. With these partnerships, Georgia and Ireland become the first countries outside of the United States in which Grindr users can order free at-home HIV self-test kits directly from links embedded in the Grindr interface, in less than one minute.

Access to HIV testing continues to be one of the biggest obstacles in the fight against the global HIV epidemic. In-person testing, in particular, poses barriers such as clinic operating hours, transportation, costs, and concerns about privacy or stigma. These barriers become even more pronounced for a variety of Grindr users, such as those living in rural areas, or those who are not “out” to their families. At-home self-testing offers users a convenient and discrete option to protect their health.

Grindr has a long history of promoting both Equality Movement and MPOWER’s home self-testing programs. As it became clear that a significant number of Grindr users needed the level of flexibility and anonymity that home self-testing provides, Grindr decided to partner with both organizations to make this easier than ever. In expanding this collaboration, Grindr emphasizes both organizations’ commitment to implementing community-level interventions and judgment-free resources.

“For the past eight years, it has been my goal to find ways to increase access to HIV testing for Grindr users, and of all the things we’ve experimented with, embedding in-app links to home self-test kits has emerged as the most powerful strategy by a considerable margin,” said Jack Harrison-Quintana, Director of Grindr For Equality. “I could not be more excited to launch partnerships similar to those with Equality Movement and MPOWER around the world.”

“Making free at-home HIV self-testing available directly through the Grindr app helps to ensure members of the LGBTQ+ community have access to vital services they need to protect their health and feel supported in their daily lives,” said Lasha Nonikashvili at Equality Movement. “We are thrilled that the LGBTQ+ community across Georgia will now be able to protect their health with an easy solution they can access from home.”

“This partnership with Grindr has the potential to revolutionize the way our community across Ireland accesses vital at-home HIV self-testing,” said Adam Shanley at MPOWER, whose mission is to devise sex-positive, judgment-free and harm reduction-based resources, services and support for gay, bisexual and MSM in Ireland. “By making these resources more widely available at home, we hope to increase access, reduce stigma, and contribute to the long-term reduction of HIV.”

Today’s announcement builds on Grindr’s commitment to achieving a meaningful impact for the LGBTQ+ community. Earlier this year, we partnered with Building Healthy Online Communities and Emory University to launch Together TakeMeHome (TTMH) with support from the U.S. Centers for Disease Control and Prevention. TTMH is a unique partnership that has distributed over 232,262 test kits within the first six months of the program. Nearly a quarter of those orders were placed by people who had never previously tested for HIV, and a majority were requested through Grindr. Grindr remains committed to launching similar programs for users around the world.

About Grindr Inc.

With more than 13 million monthly active users in virtually every country in the world, Grindr has grown to become a fundamental part of the LGBTQ+ community since its launch in 2009. The company continues to expand its ecosystem to enable gay, bi, trans, and queer people to connect, express themselves, and discover the world around them. Grindr’s impact is further driven by Grindr for Equality’s wide-ranging initiatives that help the LGBTQ+ community around the world. Grindr is headquartered in West Hollywood, California. The Grindr app is available on the App Store and Google Play.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231120646279/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye